Prognostic relevance of cytogenetics determined by flourescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia

Cancer

Volumn 107, Issue 12, 2006, Pages 2801-2806

  Strasser Weippl, Kathrin ^a   Steurer, Michael ^b   Kees, Mathias ^c   Augustin, Florian ^b   Tzankov, Alexander ^d   Dirnhofer, Stephan ^e   Fiegl, Michael ^b   Simonitsch Klupp, Ingrid ^c   Gisslinger, Heinz ^c   Zojer, Niklas ^a   Ludwig, Heinz ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Cytogenetic abnormalities; Myelofibrosis; Prognosis

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; CORTISONE; DEFEROXAMINE; FORMALDEHYDE; HYDROXYUREA; IMATINIB; PARAFFIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CELL CLONE; CELL PROLIFERATION; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; METAPHASE; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; SENSITIVITY ANALYSIS; SPLENECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHROMOSOME ABERRATIONS; CYTOGENETICS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 33845589571     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22318     Document Type: Article

References (13)

1. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981-1983.
2. Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia. 1988;2:658-660.
3. Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol. 1994;86:253-258.
4. Ruutu T, Partanen S, Knuutila S. Clonal karyotype abnormalities in erythroid and granulocyte-monocyte precursors in polycythaemia vera and myelofibrosis. Scand J Haematol. 1983;31:253-256.
5. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.
6. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113: 763-771.
7. Reilly IT, Snowden IA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98:96-102.
8. Demory JL, Dupriez B, Fenaux P, et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood. 1988;72:855-859.
9. Tefferi A, Meyer RG, Wyatt WA, Dewald GW. Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;115:316-319.
10. Strasser-Weippl K, Steurer M, Kees M, et al. Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood. 2005;105: 4146.
11. Strasser-Weippl K, Steurer M, Kees M, et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma. 2006;47: 441-450.
12. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
13. Tefferi A, Dingli D, Li CY, Dewald GW. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer. 2005;104:1656-1660.